000 01437 a2200409 4500
005 20250517123513.0
264 0 _c20181024
008 201810s 0 0 eng d
022 _a1879-0593
024 7 _a10.1016/j.oraloncology.2016.10.020
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDaste, Amaury
245 0 0 _aImmunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
_h[electronic resource]
260 _bOral oncology
_c01 2017
300 _ae1-e3 p.
_bdigital
500 _aPublication Type: Case Reports; Letter
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aCarcinoma, Squamous Cell
_xpathology
650 0 4 _aDisease Progression
650 0 4 _aHead and Neck Neoplasms
_xpathology
650 0 4 _aHumans
650 0 4 _aImmunotherapy
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNivolumab
650 0 4 _aSquamous Cell Carcinoma of Head and Neck
700 1 _ade Mones, Erwan
700 1 _aDigue, Laurence
700 1 _aFrançois, Louis
700 1 _aDomblides, Charlotte
700 1 _aDupin, Charles
700 1 _aBigourdan, Antoine
700 1 _aRavaud, Alain
773 0 _tOral oncology
_gvol. 64
_gp. e1-e3
856 4 0 _uhttps://doi.org/10.1016/j.oraloncology.2016.10.020
_zAvailable from publisher's website
999 _c26581008
_d26581008